Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a add-on therapy in nucleoside analogue-treated chronic hepatitis B patients
ChiCTR-IPR-17012242Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: HBsAg level and HBsAb level. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-IPR-17012242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012242.